AstraZeneca signs agreement to acquire TeneoTwo
Following the acquisition, AstraZeneca plans to advance the development of TNB-486 for B-cell hematologic malignancies.

Following the acquisition, AstraZeneca plans to advance the development of TNB-486 for B-cell hematologic malignancies.
In lab testing, Hoffmann-La Roche’s RG7834 showed potential to lower the ability of the virus to cause liver injury in…
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
At the closing of the deal, Blueprint will get a total of $575m in cash.
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
The filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR…
Thank you for subscribing to Pharmaceutical Technology